ZAGENO on Growth Trajectory - Startup Becoming #1 Online Marketplace for Life Science Research Products; Raises $8 Million
BOSTON, Mass., USA, and BERLIN, GERMANY, Oct. 25, 2017 (GLOBE NEWSWIRE) -- ZAGENO Inc., announces successful Series A investment of $8 Million US Dollars led by Capnamic Ventures, with Grazia Equity, lead investor in the seed round, also investing. The investment will be used to fuel growth in the key markets USA and Europe, by ramping up sales, marketing, and technical integration teams.
ZAGENO Launching a New Era of Digital Science and Research
"Just two years old, we are experiencing enormous traction, where global leaders in life science research, such as The Babraham Institute, choose to purchase life science research products through us," said Co-Founder and CEO of ZAGENO David Pumberger. "There is a vast need for digitalization in science and research! We founded ZAGENO with the vision of connecting scientists, administrative departments, and vendors of biotechnology products via one single platform, thereby creating a WIN-WIN-WIN-Situation for everybody involved. Nobody has dared to do that so far," he continued.
What is the WIN-WIN-WIN-situation for scientists, academic research institutes, researching companies, and equipment vendors? For the first time, ZAGENO enables scientists in their laboratories to choose crucial products directly via an online marketplace, from an extensive and high-quality product portfolio. Currently, researchers from 250+ leading research institutions in the U.S. and Europe compare products every day on ZAGENO for their experiments and order directly from across 650+ different vendors. This newly unveiled transparency is an absolute novelty in the biotech industry and saves costs as well as time for researchers.
ZAGENO enables straightforward integration of ordering and purchasing processes into existing software systems. And it is a milestone in the direction of bundled, and therefore, more-efficient, operation flows for academic research institutes and research companies alike. Biotechnology vendors benefit from the ZAGENO online-platform by reaching potential customers right at the buying/decision-making moments. They can also leverage ZAGENO as an additional digital sales channel to increase their reach in the key markets - USA and Europe. Further, the ZAGENO online-platform represents a valuable marketing tool to strengthen brand awareness and foster brand image and thus helps industry players to adapt to existing e-commerce models by increased customer service and content quality.
Commenting on The Babraham Institute's experience with ZAGENO, Michael Norden, the Institute's head of purchasing, said, "ZAGENO enables our 200+ scientists to choose and order life science research products from all vendors using one platform. This further streamlines our purchasing processes and allows us to gain full transparency on our spending. Ultimately, scientists focus on their research while complying with all purchasing requirements. We have found ZAGENO's customer service to be outstanding."
"ZAGENO combines an exceptional team and is the first to unlock an untapped billion dollar U.S. market," said Capnamic Ventures General Partner Christian Siegele.
Founding Partner of Grazia Equity Alec Rauschenbusch commented, "ZAGENO is fantastic. It's a true game-changer, helping the life science industry become more successful."
ZAGENO's Pumberger added, "Together with our partners and the Series A funding, we will strengthen our position at the interface of technology and biotech, as well as reach our targeted growth in focus markets. We feel very fortunate to grow together with Capnamic Ventures and Grazia Equity and to benefit from their deep industry connections and insights. Consistent with entrepreneurial values, mindsets, and growth targets, we focus on fulfilling customers' needs on all sides of the platform!"
About Capnamic Ventures
Capnamic Ventures (www.capnamic.com) is one of Europe's leading early-stage Venture Capital firms, with offices in Berlin and Cologne. The VC invests most of its funds in tech startups in the German-speaking region. Capnamic also joins forces with international co-investors. All portfolio companies are supported through Capnamic's global network of investors and industry partners.
The vast expertise of the Capnamic team includes more than 70 investments, a high turnover of successful trade sales and IPOs, as well as a strong entrepreneurial track record within the investment team. The general partners are Jörg Binnenbrücker (@bibrue), Olaf Jacobi (@olafjacobi) and Christian Siegele.
For more details, visit capnamic.com or @Capnamic on Twitter.
About Grazia Equity
Grazia Equity, one of Germany's top venture capital firms, has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. Grazia's success derives from a partnership with extraordinarily strong entrepreneurial teams to turn them into international market leaders. In contrast to other venture capital firms Grazia has a solid permanent capital structure ("Evergreen"). Grazia's portfolio companies profit from the entrepreneurial background and the business development expertise of its partner team as well as a far-reaching international network. Being active in Germany, Europe and in the USA Grazia has invested early in category leaders such as Statista, Mister Spex, Conergy, Quantenna, and Yeay.
For more information, please visit grazia.com
About ZAGENO Inc.
Since its formation in 2015, ZAGENO Inc. sets new standards in the international biotech market. With the vision to offer an online marketplace connecting scientists, academic research institutes, and biotech manufacturers, ZAGENO grows exponentially and represents a milestone for the digitization of science and research. World-renowned research facilities use ZAGENO for ordering lab equipment and for optimizing internal processes. The start-up employs 35 staff members in Boston (USA) and Berlin (Germany). These two locations were selected to be close to centers known for research advancements and scientific breakthroughs. For more "EUREKA"-moments - welcome to ZAGENO: https://zageno.com/
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8f25a44f-43ac-4555-89c9-88e214485457
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4121b588-dce2-4b4c-81f5-1375ea13b05b
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b62c1ccf-4885-4563-813c-5f4596194fd2
Media Contact: Caroline Grossman
Company Contact: Florian Wegener, MD, PhD, MBA, Chief Revenue Officer
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
BIMobject AB: Kallelse till extra bolagsstämma den 5 september 2018. Patrick Söderlund och Hjalmar Winbladh föreslås som nya styrelseledamöter i BIMobject AB. Split 2:1 föreslås.15.8.2018 15:30 | Pressmeddelande
Aktieägare representerande cirka 49 procent av rösterna i BIMobject AB har meddelat att de föreslår att Hjalmar Winbladh och Patrick Söderlund väljs till nya styrelseledamöter vid en extra bolagsstämma onsdagen den 5 september 2018. Ben O'Donnell lämnar sitt uppdrag som styrelseledamot i samband med den extra bolagsstämman. Styrelsen kommer därefter att bestå av Stefan Larsson (VD), Anders Wilhjelm (ordförande), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh och Patrick Söderlund. Vidare föreslås ändrad ersättning till styrelsen. Nytt arvode utgår med 800 000 kronor, fördelat mellan styrelseordförande och Söderlund om 400 000 kronor vardera. Styrelsen föreslår även att stämman beslutar om aktieuppdelning av befintliga utestående aktier i förhållande 2:1. Patrick Söderlund, född 1973 och svensk medborgare, är Chief Design Officer samt Executive Vice President på Electronic Arts. I denna roll leder han utvecklingen av bolagets tekniska innovationer och bolagets marknadsföringsteam
BIMobject AB: Notice to attend Extraordinary General Meeting on September 5, 2018. Patrick Söderlund and Hjalmar Winbladh proposed as new Board Members in BIMobject AB. A split 2:1 is proposed.15.8.2018 15:30 | Pressmeddelande
Shareholders representing approximately 49 percent of the votes in BIMobject AB have announced that they propose that Hjalmar Winbladh and Patrick Söderlund are appointed new Board Members at an Extraordinary General Meeting to be held on Wednesday September 5, 2018. Ben O'Donnell resigns as Board Member in connection with the Extraordinary General Meeting. The Board will thereafter be composed of Stefan Larsson (CEO), Anders Wilhjelm (Chairman), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh and Patrick Söderlund. Furthermore, a change in remuneration to the Board is proposed. The new Board fee totals SEK 800,000 and is to be divided between the Chairman and Söderlund with SEK 400,000 each. The board also proposes that the General Meeting resolves to split the company's shares 2:1. Patrick Söderlund, born in 1973 and a Swedish citizen, is Chief Design Officer and Executive Vice President at Electronic Arts. In his present role he manages the development of technology innovation
BIMobject AB: Offentliggörande av delårsrapport april - juni 201815.8.2018 08:00 | Pressmeddelande
Den fullständiga rapporten finns även tillgänglig på bolagets hemsida (info.bimobject.com). Andra kvartalet 2018 Faktureringen ökade med 83 procent och uppgick till 33 MSEK (18). Koncernens nettoomsättning ökade med 75 procent och uppgick till 28 MSEK (16). Fördelning mellan projekt och webservices (prenumerationer) var 40/60 procent (60/40). Bruttomarginalen ökade till 86 procent (81). Koncernens rörelseresultat förbättrades och uppgick till -15 MSEK (-17). Resultat per aktie uppgick till -0,29 SEK (-0,31) före utspädning. Kassaflödet från löpande verksamheten uppgick till -18 MSEK (-15). Ackumulerat antal användare ökade och uppgick till cirka 845 000. Ackumulerat antal nedladdningar uppgick till 25,5 miljoner. Antalet tillverkare uppgick till 1230. Styrelsen beslutade att påbörja processen för notering av bolaget vid Nasdaq Stockholm. Viktiga händelser andra kvartalet BIMobject ingår samarbete med Pipe Retail Solution för att effektivisera digital butiksplanering. BIMobject tecknar
BIMobject AB: Interim Report April - June 201815.8.2018 08:00 | Pressmeddelande
Second quarter 2018 Billing increased by 83 percent to SEK 33 (18) million. The Group's net sales increased by 75 percent to SEK 28 (16) million. The distribution between projects and web services (subscriptions) was 40/60 (60/40) percent. The gross margin increased to 86 (81) percent. The Group's operating profit improved to SEK -15 (-17) million. Basic earnings per share amounted to SEK -0.29 (-0.31). Cash flow from operating activities was SEK -18 (-15) million. The accumulated number of users increased to approximately 845,000. The accumulated number of downloads amounted to 25.5 million. The number of manufacturers was 1,230. The Board decided to initiate the process of listing the Company on Nasdaq Stockholm. Significant events during the second quarter BIMobject forms strategic partnership with Pipe Retail Solution to streamline digital planning of retail spaces. BIMobject signs Letter of Intent with leading US 3D media company Matterport. CEO's comments EQT Ventures' investment
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00 | Pressmeddelande
Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H
Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00 | Pressmeddelande
Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum